Treatment with donepezil, an AChE inhibitor, was associated with upregulated serum BDNF levels in AD patients mimicking those of healthy control levels, perhaps suggesting that AChE inhibitors exhibit their neuroprotective effects via a mechanism involving increasing BDNF levels [48]. Here, BDNF is linked to Alzheimer disease.